Otros idiomas FluoGuide A/S

Acciones

FLUO

DK0061123312

Mercado cerrado - Nasdaq Stockholm Otros sitios de cotización 16:48:58 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
48,9 ^SEK	+7,47 %		+9,27 %	-20,10 %

20/03	FluoGuide A/S aprueba cambios en la junta directiva	CI
12/03	FluoGuide A/S inicia una colaboración con Intuitive Surgical, Inc en el ámbito de la cirugía del cáncer de cabeza y cuello asistida por robot	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

FluoGuide A/S Approves Board Changes	20/03
Minutes from Annual General Meeting in FluoGuide A/S	20/03
Chief Financial Officer (CFO) Ole Larsen buys shares	13/03
FluoGuide enters collaboration within robot assisted head and neck cancer surgery with Intuitive Surgical, a world leading robotic-assisted surgery company	12/03
FluoGuide A/S Enters Collaboration Within Robot Assisted Head and Neck Cancer Surgery with Intuitive Surgical, Inc	12/03
Notice of Annual General Meeting in FluoGuide A/S	01/03
Fluoguide Q4 2023 - Bright prospects	28/02
FluoGuide A/S publishes year-end and annual report for the fiscal year 2023	28/02
FluoGuide A/S Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
FluoGuide A/S issues warrants to CFO	23/02
FluoGuide A/S Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001	08/01
FluoGuide provides strategic update and outlines development plans towards commercialization of FG001	08/01
FluoGuide raises SEK 12 million through exercise of warrants	11/12
Chief Development Officer (CDO) Grethe Nørskov Rasmussen sells shares	09/12
FluoGuide raises SEK 12 million through exercise of warrants	08/12
Fluoguide Q3 2023 - Spoilt for choice	29/11
FluoGuide A/S publishes interim report for the period January – September 2023	29/11
FluoGuide A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11
FluoGuide announces FG001 meets primary endpoint in phase llb trial in aggressive brain cancer	13/11
FluoGuide A/S Announces FG001 Meets Primary Endpoint in Phase LLB Trial in Aggressive Brain Cancer	13/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas FluoGuide A/S

Acciones

FLUO

DK0061123312

Otros idiomas

Filtros